Scarica l'app Stockscreener
7.98
7.68%
0.5691
Dopo l'orario di chiusura:
7.98
Precedente Chiudi:
$7.4109
Aprire:
$7.61
Volume 24 ore:
3,272
Relative Volume:
0.50
Capitalizzazione di mercato:
$36.83M
Reddito:
$2.61M
Utile/perdita netta:
$1.69M
Rapporto P/E:
26.57
EPS:
0.3003
Flusso di cassa netto:
-
1 W Prestazione:
+0.38%
1M Prestazione:
-4.20%
6M Prestazione:
-12.60%
1 anno Prestazione:
-18.15%
Intervallo 1D:
$7.61
$7.98
Intervallo di 1 settimana:
$7.346
$8.1933
Portata 52W:
$6.55
$10.00
Daxor Corporation Stock (DXR) Company Profile
Nome
Daxor Corporation
Settore
Industria
Telefono
212-330-8500
Indirizzo
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
Confronta DXR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
7.98 | 36.83M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
468.32 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
196.61 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
91.38 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
210.87 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
78.70 | 15.58B | 3.90B | 392.30M | 288.10M | 1.95 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-05-16 | Iniziato | Ascendiant Capital Markets | Buy |
Daxor Corporation Borsa (DXR) Ultime notizie
(DXR) Trading Report - news.stocktradersdaily.com
Daxor Corporation to Showcase Innovative Blood Volume - GlobeNewswire
Daxor (DXR) to Exhibit at MedAxiom CV Transforum Spring'25 Conference | DXR Stock News - GuruFocus
Daxor to showcase blood volume analysis at Cardiovascular Transforum conference - TipRanks
Revolutionary Blood Volume Technology Slashes Mortality Rates by 82%Groundbreaking Clinical Results Unveiled - Stock Titan
Daxor announces new data at ACC on blood volume analysis - TipRanks
Daxor (DXR) Unveils Promising Heart Failure Study Results at ACC Conference | DXR Stock News - GuruFocus
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic - GlobeNewswire
Breakthrough Heart Failure Study: Daxor BVA Test Doubles Patient Survival Rates - Stock Titan
Daxor (DXR) Submits Next-Gen Blood Analyzer to FDA for Approval - GuruFocus
Daxor submits new blood volume analyzer to FDA By Investing.com - Investing.com South Africa
Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer - marketscreener.com
Daxor submits new blood volume analyzer to FDA - Investing.com
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer - GlobeNewswire
Revolutionary Blood Volume Analyzer With Military Backing Advances Toward FDA Green Light - Stock Titan
CEO’s Bold Move: Major Investment in Daxor Stock - TipRanks
Daxor CEO Michael Feldschuh purchases over $16,000 in stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases over $16,000 in stock - Investing.com Australia
DAXOR CEO Michael Richard Feldschuh Buys 2,063 Shares - TradingView
Where are the Opportunities in (DXR) - news.stocktradersdaily.com
Daxor Corporation (NASDAQ:DXR) Q4 2024 Earnings Call Transcript - MSN
Daxor (NYSEAMERICAN:DXR) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Daxor announces new data from Duke University on BVA at ACC - TipRanks
Daxor’s BVA technology gains traction at cardiology event - Investing.com
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo - GlobeNewswire
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo - The Manila Times
Duke Research Reveals Why Daxor's Blood Test Outperforms Traditional Heart Failure Methods - Stock Titan
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks - GlobeNewswire
Daxor Expands to 3 New Locations in New Jersey, Midwest - MarketScreener
Breakthrough Blood Volume Tech With 98% Accuracy Gains Major Healthcare Adoption - Stock Titan
Daxor CEO Michael Feldschuh purchases $8,130 in company shares - Investing.com
Daxor CEO Michael Feldschuh purchases $8,130 in company shares By Investing.com - Investing.com UK
Daxor CEO Feldschuh buys shares worth $5,273 By Investing.com - Investing.com Canada
Daxor CEO Feldschuh buys shares worth $5,273 - Investing.com
Ascendiant Capital Markets Issues Positive Forecast for Daxor (NASDAQ:DXR) Stock Price - The AM Reporter
Daxor (NASDAQ:DXR) Given New $25.00 Price Target at Ascendiant Capital Markets - Defense World
(DXR) Investment Analysis and Advice - Stock Traders Daily
Daxor Corporation Reports Strong 2024 Financial Growth - TipRanks
Daxor CFO Michel Robert J purchases $8,000 in company stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases $25,804 in company stock - Investing.com
Daxor CFO Michel Robert J purchases $8,000 in company stock - Investing.com
Daxor Corporation Reports Robust Growth in Earnings Call - TipRanks
Earnings call transcript: Daxor Q4 2024 sees 116.5% revenue growth - Investing.com India
Earnings call transcript: Daxor Q4 2024 sees 116.5% revenue growth By Investing.com - Investing.com UK
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - GlobeNewswire
Daxor Corporation Azioni (DXR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.50%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):